Managed Care Considerations for Advances in Anticoagulation Reversal Therapy Home Study

ACPE UAN #: 0233-0000-18-047-L04-P

Release Date:  June 26, 2018

Expiration Date:  June 26, 2021

Activity Type:  Knowledge-based  

Credit Hours:  1.0 contact hours (0.1 CEU)

Activity Fee:  There is no fee to participate in this home study activity. 

Target Audience

This home study activity has been designed to meet the educational needs of pharmacists in managed care settings.

Activity Overview:

The advent of the direct acting oral anticoagulants (DOACs) has provided a convenient alternative to traditional anticoagulation with warfarin or low-molecular weight heparins. The DOACs have proven benefits for stroke prevention, and for both treatment and prevention of venous thromboembolism (VTE). The DOACs all carry the risk of major bleeding. Delineating the differences in the bleeding rates between products and the resulting economic impact is essential in determining the most appropriate anticoagulant for an individual patient.

This program will compare the prevalence of bleeding between the individual agents, address the economic impact of major bleeds, and discuss current techniques for managing excessive anticoagulation. Additionally, the mechanisms of action and available efficacy data for currently approved and investigational anticoagulant reversal agents will be presented.

Learning Objectives 

At the completion of this activity, participants should be able to:

  1. Detail the impact of major bleeds per anticoagulant agent in terms of prevalence, patient outcomes, and economic impact.
  2. Discuss current strategies for the treatment of direct oral anticoagulants (DOACs) associated bleeding.
  3. Identify at least one currently marketed and one investigational anticoagulant reversal product, and outline where each medication may fit into current anticoagulation bleeding treatment guidelines.

Schedule of Educational Activity

  • Managed Care Considerations for Advances in Anticoagulation Reversal Therapy - Angela A. Allerman, PharmD, BCPS 

CPE Requirements:   

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live webinar activity on June 26, 2018.  CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites.  View the minimum technical and system requirements for continuing education online learning activities.

As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

Statement of Commercial Support

This educational activity is supported by an unrestricted educational grant from Portola Pharmaceuticals, Inc.

Moderator:

Christine L. Cooper, PharmD
Education Program Manager
Academy of Managed Care Pharmacy
Alexandria, Virginia

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-18-047-H04-P 1 Contact Hour June 26, 2018 - June 26, 2021